SCHEMBL734459

SCHEMBL734459

CC1C(=O)NCCN1c1ccc(Cl)c(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BCL2A1 Q16548 1/20 0.54
AR P10275 1/20 0.46
NOTUM Q6P988 11/20 0.44
ADAMTS5 Q9UNA0 2/20 0.43
HTR2C P28335 4/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTR2A P28223 1/20 0.40
HTR2B P41595 1/20 0.40
MMP2 P08253 1/20 0.40
MMP14 P50281 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735198 0.85 BCL2A1 (0.43) BCL2A1ARADAMTS5HTR2CHTR2A
SCHEMBL734818 0.81 SIRT6 (0.54) BCL2A1ARMEN1CYP1A2CYP3A4
SCHEMBL5633391 0.77 HTR2C (0.48) ARNOTUMADAMTS5HTR2CHTR2A
SCHEMBL30609630 0.77 HTR2C (0.48) ARNOTUMADAMTS5HTR2CHTR2A
SCHEMBL5632346 0.77 HTR2C (0.48) ARNOTUMADAMTS5HTR2CHTR2A
SCHEMBL734584 0.77 HTR2C (0.49) BCL2A1ARHTR2CMEN1CYP1A2
SCHEMBL5632335 0.77 HTR2C (0.48) ARNOTUMADAMTS5HTR2CHTR2A
Hydrochloric Acid SCHEMBL2270866 0.76 HTR2C (0.47) ARNOTUMADAMTS5HTR2CHTR2A
Hydrochloric Acid SCHEMBL5631778 0.76 HTR2C (0.47) ARNOTUMADAMTS5HTR2CHTR2A
Hydrochloric Acid SCHEMBL5633063 0.76 HTR2C (0.47) ARNOTUMADAMTS5HTR2CHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 BCL2A1 2457/4885AR 811/4885NOTUM 4344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.